Ketamine for Parkinson's - Phase 2 Trials are Underway

We are beginning to see a trend for the application of psychedelics beyond psychiatry, to neurological conditions such as stroke, Alzheimers and Parkinson's. Indeed, this week PharmaTher Holdings (a clinical stage psychedelic company) announced that is has initiated its Phase 2 trials evaluating the therapeutic potential of Ketamine for Parkinson's (more specifically, for Levodopa-Induced Dyskinesia). Results are expected to be published in late Q4 2021.

Highlights: "The Phase 2 KET-LID clinical trial is a randomized, double-blind, active placebo-controlled study evaluating the safety, efficacy and pharmacokinetics of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease".

The company states that the "primary and secondary endpoints are the changes in the following: i) total score of the Unified Dyskinesia Rating Scale (UDysRS), ii) total objective score (III, IV) of the UDysRS, iii) total daily OFF times as assessed by subject- completed 24-hour diaries, and iv) Unified Parkinson’s Disease Rating Scale (UPDRS) total score of part III (motor) and sum score of Questions 4.1 and 4.2 (dyskinesia) in part IV".

For more psychedelic news and research, visit the psychedelic health professional network homepage.